Mike Dennis is a Clinical Haematologist who is an established national expert in myeloid disease. His expertise is in the management of acute myeloid leukaemia (AML), myelodysplasia (MDS), chronic myeloid leukaemia (CML), other associated myeloproliferative disorders (Myelofibrosis, CMML, ET, PRV) and bone marrow failure syndromes (including aplastic anaemia). This includes diagnosis and therapy (including stem cell transplantation) He is a committee member of the NCRN working groups for AML and myelodysplasia, where his research roles include Chief investigator (Li1) and Co-chief investigator (AML 19) of the UK's premier front line AML studies. His research focus is about getting access for patients to the most effective emerging agents. This is through clinical trial development of optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance and oversight. He was appointed as a Consultant Haematologist at The Christie, Manchester in 2004. He qualified in Medicine from the University of Dundee, completed his physician’s training in Liverpool before undertaking his first Haematology post in Australia. He then completed his Haematology training, including a MD, from the University of Liverpool.